Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Galsky on Sequencing Questions in Urothelial Cancer

June 23rd 2020

Matthew Galsky, MD, discusses sequencing questions in urothelial carcinoma.

Dr. Lee on the Combination of Immunotherapy and TKIs in mRCC

June 17th 2020

Chung-Han Lee, MD, PhD, discusses the efficacy of combining immunotherapy with TKIs to treat patients with metastatic renal cell carcinoma.

Sequential Nivolumab and Ipilimumab Regimen Does Not Show Benefit in mRCC

June 10th 2020

Rana R. McKay, MD, discusses the design and key findings of the OMNIVORE trial, as well as other ongoing adaptive trials in renal cell carcinoma.

Pembrolizumab Combo Falls Short in Phase 3 Frontline Urothelial Carcinoma Trial

June 10th 2020

Adding pembrolizumab to chemotherapy did not lead to a statistically significant improvement in overall survival or progression-free survival in patients with advanced or metastatic urothelial carcinoma, according to findings from the phase 3 KEYNOTE-361 trial.

Sequential Nivolumab and Ipilimumab Regimen Does Not Show Benefit in mRCC

June 10th 2020

Rana R. McKay, MD, discusses the design and key findings of the OMNIVORE trial, as well as other ongoing adaptive trials in renal cell carcinoma.

Pembrolizumab Combo Falls Short in Phase 3 Frontline Urothelial Carcinoma Trial

June 10th 2020

Pal Previews Promise of Cabozantinib Plus Atezolizumab in Heavily Pretreated Urothelial Cancer

June 9th 2020

Sumanta K. Pal, MD, discusses the clinical implications of the COSMIC-021 trial and highlights other exciting research efforts being made in genitourinary cancers.

Pal Previews Promise of Cabozantinib Plus Atezolizumab in Heavily Pretreated Urothelial Cancer

June 9th 2020

Sumanta K. Pal, MD, discusses the clinical implications of the COSMIC-021 trial and highlights other exciting research efforts being made in genitourinary cancers.

Dr. Sfakianos on the Utility of Adjuvant Therapy in Bladder Cancer Management

June 3rd 2020

John P. Sfakianos, MD, discusses the utility of adjuvant therapy in bladder cancer management.

Dr. Plimack on Updated Findings of the KEYNOTE-426 Study in RCC

June 2nd 2020

Elizabeth R. Plimack, MD, MS, discusses the updated findings from the phase 3 KEYNOTE-426 study in patients with previously untreated, advanced renal cell carcinoma.

Infigratinib Demonstrates Clinical Activity Across Settings in Urothelial Cancer

June 2nd 2020

Infigratinib was found to demonstrate clinical activity in patients with metastatic urothelial carcinoma, regardless of what line of therapy it was administered.

FDA Accepts Application for Tivozanib in Relapsed/Refractory RCC

June 1st 2020

The FDA has accepted a new drug application for tivozanib for the treatment of patients with relapsed/refractory renal cell carcinoma.

IMvigor010 Misses DFS End Point in Muscle-Invasive Urothelial Carcinoma

May 31st 2020

The phase 3 IMvigor010 trial comparing adjuvant atezolizumab with observation in patients with muscle-invasive urothelial carcinoma failed to meet its primary endpoint of disease-free survival.

Cabozantinib Maintains Efficacy in Advanced RCC Irrespective of Prior Treatment

May 31st 2020

Patients with advanced renal cell carcinoma who were treated with cabozantinib (Cabometyx) following both immunotherapy and non-IO regimens demonstrated promising responses.

Frontline Pembrolizumab/Axitinib Survival Benefit Upholds in Advanced RCC

May 31st 2020

The combination of pembrolizumab and axitinib continued to demonstrate a clinically significant improvement in progression-free and overall survival compared with sunitinib in patients with previously untreated, advanced renal cell carcinoma.

Savolitinib Shows Promising Efficacy Data in Papillary Renal Cell Carcinoma

May 29th 2020

Savolitinib showed encouraging efficacy data and an improved safety profile versus sunitinib as a treatment for patients with MET-driven papillary renal cell carcinoma.

Tivozanib Showcases Superiority in Relapsed/Refractory RCC

May 29th 2020

Tivozanib demonstrated a significant improvement in progression-free survival when compared with sorafenib, with similar overall survival, in patients with highly relapsed or refractory metastatic renal cell carcinoma.

Dr. Choueiri on Results of the SAVOIR Trial in MET-Driven Papillary RCC

May 29th 2020

Toni K. Choueiri, MD, discusses results of the phase 3 SAVOIR trial evaluating the MET inhibitor savolitinib versus sunitinib in patients with MET-driven papillary renal cell carcinoma.

Avelumab Extends Survival as Frontline Maintenance in Urothelial Carcinoma

May 29th 2020

Adding avelumab to best supportive care improved the median overall survival by over 7 months in patients with locally advanced or metastatic urothelial carcinoma, according to findings from the phase 3 JAVELIN Bladder 100 study.

Dr. Powles on Maintenance Avelumab in Urothelial Carcinoma

May 29th 2020

Thomas Powles, MD, MBBS, MRCP, discusses the utility of maintenance avelumab in the phase 3 JAVELIN Bladder 100 study in advanced urothelial carcinoma.